Proliferative Vitreoretinopathy Prevention Drug Granted Orphan Drug Designation

Tetra Bio-Pharma Inc has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its synthetic cannabinoid PPP003 (HU308) for the prevention of proliferative vitreoretinopathy, according to a press release.  "Our research in an experimental model of PVR has demonstrated that the synthetic cannabinoid, PPP003, can prevent this condition...